Using SIK activators to treat bone diseases linked to parathyroid hormone
Official title: SIK Activators to Treat PTH Pathway Bone Diseases
Funded at Rutgers Biomedical and Health Sciences · NIH-11175152 · Data updated 2026-11-12
This study is looking at how certain treatments might help people with bone problems caused by an overactive parathyroid hormone, like hyperparathyroidism, by exploring how these treatments can change the way bone cells work and possibly fix the damage done to bones.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | August 22, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $280,267 |
| NIH project number | 7R21AR082666-02 |
| Project ID | NIH-11175152 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with hyperparathyroidism or genetic bone disorders such as Jansen’s metaphyseal chondrodysplasia or Fibrous Dysplasia-McCune-Albright Syndrome.
✕Less likely to help
Patients with bone diseases not related to parathyroid hormone signaling may not benefit from this research.
What this research studies
This research investigates the role of SIK activators in treating bone diseases caused by an overactive parathyroid hormone receptor. It focuses on conditions like hyperparathyroidism and genetic disorders that lead to severe skeletal issues. The approach involves studying how these activators can influence bone cell behavior and potentially reverse the damaging effects of the overactive signaling pathways. By using a specialized mouse model, researchers aim to understand the underlying mechanisms and develop new therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve bone health and quality of life for patients with specific bone diseases.
How similar studies have gone: While the specific approach of using SIK activators is novel, similar research has shown promise in targeting signaling pathways for bone disease treatment.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Le Henaff, Carole Anne — Rutgers Biomedical and Health Sciences
- Study coordinator: Le Henaff, Carole Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.